Table 1.

Correlation Between ACTL6A Expression With Clinicopathological Characteristics of HCC in Training and Validation Cohort

	Training Cohort				Validation Cohort
Clinicopathological Variables		ACTL6A Expression				ACTL6A Expression
	n	High (73)	Low (27)	P Value	n	High (43)	Low (20)	P Value
Sex
Female	31	22	9		22	16	6
Male	69	51	18	0.759	41	27	14	0.576
Age, years
<50	62	43	19		37	24	13
≥50	38	30	8	0.294	26	19	7	0.491
AFP, ng/mL
<20	43	26	17		25	15	10
≥20	57	47	10	0.014	38	28	10	0.254
HBsAg
Negative	7	6	1		6	4	2
Positive	93	67	26	0.731	57	39	18	0.583
Liver cirrhosis
Absence	35	24	11		21	13	8
Presence	65	49	16	0.464	42	30	12	0.444
Liver function
Child‐Pugh A	91	66	25		56	38	18
Child‐Pugh B	9	7	2	0.464	7	5	2	0.534
Tumor size, cm
≤5	38	25	13		19	12	7
>5	62	48	14	0.204	44	31	13	0.568
Tumor nodule number
Solitary	57	36	21		30	16	14
Multiple (≥2)	43	37	6	0.011	33	27	6	0.015
Capsulation formation
Presence	42	29	13		26	15	11
Absence	58	44	14	0.449	37	28	9	0.131
Edmondson‐Steiner grade
I & II	64	42	22		39	24	15
III & IV	36	31	5	0.014	24	19	5	0.082
Microvascular invasion
Absence	34	19	15		25	13	12
Presence	66	54	12	0.006	38	30	8	0.025
BCLC stage
0 & A	28	16	12		18	7	11
B & C	72	57	15	0.026	45	36	9	0.002
TNM stage
Early (I & II)	67	44	23		35	21	14
Late (III & IV)	33	29	4	0.010	28	22	6	0.116

No patients with Child‐Pugh C were included. ACTL6A low expression: IHC score 0‐1; ACTL6A high expression: IHC score 2‐4.

^* Significant results (P < 0.05) are given in bold.

Abbreviation: HBsAg, hepatitis B surface antigen.